Kartik Viswanathan1, Ying-Hsia Chu2, William C Faquin1, Peter M Sadow1. 1. Departments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: NTRK-rearranged thyroid carcinomas (NRTC), though rare, harbor a potential therapeutic target. The cytomorphologic features by fine needle aspiration (FNA) and the utility of preoperative molecular testing for NRTC remain largely uncharacterized. We provide a detailed cytomorphologic analysis of an institutional NRTC cohort with clinical, radiologic, histopathologic, and molecular correlations. METHODS: Our NRTC FNA cohort included 21 specimens from 19 patients. The mean age and female-to-male ratio were 42 years and 2.2:1, respectively. Predominantly alcohol-stained Papanicolaou smears and liquid-based preparations were reviewed for 14 patients with available materials, and histologic review of subsequent resections was conducted for all 19 patients. Imaging and clinical data were accessed through electronic medical records. RESULTS: Sonographically, NRTC were hypoechoic (87%), predominantly solid (53%) with limited central vascularity (27%), ill-defined borders (67%), and microcalcifications (67%). Observed cytomorphologic features include mixed architectural patterns (79%), fibrosis (93%), oncocytic and vacuolated cytoplasm (36% and 43%, respectively), and abundant intranuclear pseudoinclusions (14%). Most NRTC FNAs were classified as suspicious for malignancy or malignant (89%). One case classified as atypia of uncertain significance underwent ThyroSeq sequencing where a NTRK1 fusion was identified. CONCLUSION: Although NRTC did not show a consistent cytomorphologic signature, mixed architectural patterns, prominent fibrosis and distinct cytoplasmic or nuclear features should raise suspicion for NRTC and, when accompanied by negative BRAFV600E by immunohistochemistry on cell block material, aid in selecting cases for molecular testing. This algorithmic approach may help identify potential NRTC, maximizing treatment options for patients, especially in patients for whom treatment planning is complicated.
BACKGROUND: NTRK-rearranged thyroid carcinomas (NRTC), though rare, harbor a potential therapeutic target. The cytomorphologic features by fine needle aspiration (FNA) and the utility of preoperative molecular testing for NRTC remain largely uncharacterized. We provide a detailed cytomorphologic analysis of an institutional NRTC cohort with clinical, radiologic, histopathologic, and molecular correlations. METHODS: Our NRTC FNA cohort included 21 specimens from 19 patients. The mean age and female-to-male ratio were 42 years and 2.2:1, respectively. Predominantly alcohol-stained Papanicolaou smears and liquid-based preparations were reviewed for 14 patients with available materials, and histologic review of subsequent resections was conducted for all 19 patients. Imaging and clinical data were accessed through electronic medical records. RESULTS: Sonographically, NRTC were hypoechoic (87%), predominantly solid (53%) with limited central vascularity (27%), ill-defined borders (67%), and microcalcifications (67%). Observed cytomorphologic features include mixed architectural patterns (79%), fibrosis (93%), oncocytic and vacuolated cytoplasm (36% and 43%, respectively), and abundant intranuclear pseudoinclusions (14%). Most NRTC FNAs were classified as suspicious for malignancy or malignant (89%). One case classified as atypia of uncertain significance underwent ThyroSeq sequencing where a NTRK1 fusion was identified. CONCLUSION: Although NRTC did not show a consistent cytomorphologic signature, mixed architectural patterns, prominent fibrosis and distinct cytoplasmic or nuclear features should raise suspicion for NRTC and, when accompanied by negative BRAFV600E by immunohistochemistry on cell block material, aid in selecting cases for molecular testing. This algorithmic approach may help identify potential NRTC, maximizing treatment options for patients, especially in patients for whom treatment planning is complicated.
Authors: Erik K Alexander; Giulia C Kennedy; Zubair W Baloch; Edmund S Cibas; Darya Chudova; James Diggans; Lyssa Friedman; Richard T Kloos; Virginia A LiVolsi; Susan J Mandel; Stephen S Raab; Juan Rosai; David L Steward; P Sean Walsh; Jonathan I Wilde; Martha A Zeiger; Richard B Lanman; Bryan R Haugen Journal: N Engl J Med Date: 2012-06-25 Impact factor: 91.245
Authors: Alexander Drilon; Theodore W Laetsch; Shivaani Kummar; Steven G DuBois; Ulrik N Lassen; George D Demetri; Michael Nathenson; Robert C Doebele; Anna F Farago; Alberto S Pappo; Brian Turpin; Afshin Dowlati; Marcia S Brose; Leo Mascarenhas; Noah Federman; Jordan Berlin; Wafik S El-Deiry; Christina Baik; John Deeken; Valentina Boni; Ramamoorthy Nagasubramanian; Matthew Taylor; Erin R Rudzinski; Funda Meric-Bernstam; Davendra P S Sohal; Patrick C Ma; Luis E Raez; Jaclyn F Hechtman; Ryma Benayed; Marc Ladanyi; Brian B Tuch; Kevin Ebata; Scott Cruickshank; Nora C Ku; Michael C Cox; Douglas S Hawkins; David S Hong; David M Hyman Journal: N Engl J Med Date: 2018-02-22 Impact factor: 91.245
Authors: Marina N Nikiforova; Marcos Lepe; Lindsey A Tolino; Megan E Miller; N Paul Ohori; Abigail I Wald; Michael S Landau; Cihan Kaya; Umberto Malapelle; Claudio Bellevicine; Giancarlo Troncone; Yuri E Nikiforov; Zubair Baloch Journal: Cancer Cytopathol Date: 2020-07-22 Impact factor: 5.284
Authors: Robert C Doebele; Alexander Drilon; Luis Paz-Ares; Salvatore Siena; Alice T Shaw; Anna F Farago; Collin M Blakely; Takashi Seto; Byung Chul Cho; Diego Tosi; Benjamin Besse; Sant P Chawla; Lyudmila Bazhenova; John C Krauss; Young Kwang Chae; Minal Barve; Ignacio Garrido-Laguna; Stephen V Liu; Paul Conkling; Thomas John; Marwan Fakih; Darren Sigal; Herbert H Loong; Gary L Buchschacher; Pilar Garrido; Jorge Nieva; Conor Steuer; Tobias R Overbeck; Daniel W Bowles; Elizabeth Fox; Todd Riehl; Edna Chow-Maneval; Brian Simmons; Na Cui; Ann Johnson; Susan Eng; Timothy R Wilson; George D Demetri Journal: Lancet Oncol Date: 2019-12-11 Impact factor: 41.316
Authors: Jeffrey F Krane; Edmund S Cibas; Mayumi Endo; Ellen Marqusee; Mimi I Hu; Christian E Nasr; Steven G Waguespack; Lori J Wirth; Richard T Kloos Journal: Cancer Cytopathol Date: 2020-06-16 Impact factor: 5.284
Authors: Steven G DuBois; Theodore W Laetsch; Noah Federman; Brian K Turpin; Catherine M Albert; Ramamoorthy Nagasubramanian; Megan E Anderson; Jessica L Davis; Hope E Qamoos; Mark E Reynolds; Scott Cruickshank; Michael C Cox; Douglas S Hawkins; Leo Mascarenhas; Alberto S Pappo Journal: Cancer Date: 2018-09-11 Impact factor: 6.860
Authors: Kartik Viswanathan; Peter M Sadow; Zahra Maleki; Michiya Nishino; Zubair W Baloch; Todd E Abbott; Rema Rao; William C Faquin Journal: Cancer Cytopathol Date: 2021-10-01 Impact factor: 4.264